Conformation-dependent Oligomers in Cerebrospinal Fluid of Presymptomatic Familial Alzheimer's Disease Mutation Carriers

Overview

Journal Dement Geriatr Cogn Dis Extra

Publisher Karger

Specialty Geriatrics

Date 2013 Jan 24

PMID 23341831

Citations 4

Authors

John M Ringman

Jennifer L Tomic

Giovanni Coppola

David Elashoff

Karen H Gylys

Charles G Glabe

Affiliations

Soon will be listed here.

Abstract

Background/aims: Oligomerization of amyloid beta (Aβ) is a hypothesized step in the formation of plaques in Alzheimer's disease (AD) but has been difficult to demonstrate in vivo in humans. As persons destined to develop familial AD (FAD) due to fully penetrant autosomal dominant mutations are essentially certain to develop the disease, they provide the opportunity to identify oligomers during the presymptomatic stage of the disease.

Methods: We measured levels of Aβ(42) using a conventional immunoassay and prefibrillar, fibrillar, and annular protofibrillar oligomers using polyclonal conformation-dependent antibodies in the cerebrospinal fluid (CSF) of 7 persons at risk for inheriting FAD mutations. Levels of oligomers were compared between FAD mutation carriers and noncarriers.

Results: Compared to 2 noncarriers, annular protofibrillar oligomers were elevated, prefibrillar and fibrillar oligomers trended towards elevation and Aβ(42) monomer trended towards being decreased in 5 FAD mutation carriers.

Conclusion: Our data provide evidence for an identifiable elevation of CSF oligomers during the presymptomatic phase of FAD.

Citing Articles

< Variant and Early-Onset Alzheimer's Disease: A Scoping Review.

Orozco-Barajas M, Oropeza-Ruvalcaba Y, Canales-Aguirre A, Sanchez-Gonzalez V Front Aging Neurosci. 2022; 14:860529.

PMID: 35959289 PMC: 9361039. DOI: 10.3389/fnagi.2022.860529.

Monoclonal antibody with conformational specificity for a toxic conformer of amyloid β42 and its application toward the Alzheimer's disease diagnosis.

Murakami K, Tokuda M, Suzuki T, Irie Y, Hanaki M, Izuo N Sci Rep. 2016; 6:29038.

PMID: 27374357 PMC: 4931470. DOI: 10.1038/srep29038.

Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis.

Viola K, Klein W Acta Neuropathol. 2015; 129(2):183-206.

PMID: 25604547 PMC: 4390393. DOI: 10.1007/s00401-015-1386-3.

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.

Lleo A, Cavedo E, Parnetti L, Vanderstichele H, Herukka S, Andreasen N Nat Rev Neurol. 2014; 11(1):41-55.

PMID: 25511894 DOI: 10.1038/nrneurol.2014.232.

References

Kayed R, Canto I, Breydo L, Rasool S, Lukacsovich T, Wu J . Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Aβ oligomers. Mol Neurodegener. 2010; 5:57. PMC: 3019145. DOI: 10.1186/1750-1326-5-57. View

Janssen J, Beck J, Campbell T, Dickinson A, Fox N, Harvey R . Early onset familial Alzheimer's disease: Mutation frequency in 31 families. Neurology. 2003; 60(2):235-9. DOI: 10.1212/01.wnl.0000042088.22694.e3. View

Lasagna-Reeves C, Glabe C, Kayed R . Amyloid-β annular protofibrils evade fibrillar fate in Alzheimer disease brain. J Biol Chem. 2011; 286(25):22122-30. PMC: 3121356. DOI: 10.1074/jbc.M111.236257. View

Hardy J, Selkoe D . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-6. DOI: 10.1126/science.1072994. View

Kayed R, Head E, Sarsoza F, Saing T, Cotman C, Necula M . Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007; 2:18. PMC: 2100048. DOI: 10.1186/1750-1326-2-18. View

Murrell J, Ghetti B, Cochran E, Macias-Islas M, Medina L, Varpetian A . The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco State, Mexico: an additional fifteen families. Neurogenetics. 2006; 7(4):277-9. PMC: 3378247. DOI: 10.1007/s10048-006-0053-1. View

Walsh D, Klyubin I, Shankar G, Townsend M, Fadeeva J, Betts V . The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans. 2005; 33(Pt 5):1087-90. DOI: 10.1042/BST20051087. View

Ringman J, Younkin S, Pratico D, Seltzer W, Cole G, Geschwind D . Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology. 2008; 71(2):85-92. DOI: 10.1212/01.wnl.0000303973.71803.81. View

Kayed R, Head E, Thompson J, McIntire T, Milton S, Cotman C . Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003; 300(5618):486-9. DOI: 10.1126/science.1079469. View

10.

Mullan M, Tsuji S, Miki T, Katsuya T, Naruse S, Kaneko K . Clinical comparison of Alzheimer's disease in pedigrees with the codon 717 Val-->Ile mutation in the amyloid precursor protein gene. Neurobiol Aging. 1993; 14(5):407-19. DOI: 10.1016/0197-4580(93)90099-w. View

11.

Klunk W, Price J, Mathis C, Tsopelas N, Lopresti B, Ziolko S . Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007; 27(23):6174-84. PMC: 3265970. DOI: 10.1523/JNEUROSCI.0730-07.2007. View

12.

Englund H, Degerman Gunnarsson M, Brundin R, Hedlund M, Kilander L, Lannfelt L . Oligomerization partially explains the lowering of Abeta42 in Alzheimer's disease cerebrospinal fluid. Neurodegener Dis. 2009; 6(4):139-47. DOI: 10.1159/000225376. View

13.

Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N . Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996; 2(8):864-70. DOI: 10.1038/nm0896-864. View

14.

Ringman J, Coppola G, Elashoff D, Rodriguez-Agudelo Y, Medina L, Gylys K . Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease. Dement Geriatr Cogn Disord. 2012; 33(1):1-5. PMC: 3696356. DOI: 10.1159/000335729. View

15.

Ringman J, Medina L, Rodriguez-Agudelo Y, Chavez M, Lu P, Cummings J . Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease. Curr Alzheimer Res. 2009; 6(4):341-6. PMC: 2887763. DOI: 10.2174/156720509788929336. View

16.

Ringman J, Taylor K, Teng E, Coppola G, Gylys K . Longitudinal change in CSF biomarkers in a presymptomatic carrier of an APP mutation. Neurology. 2011; 76(24):2124-5. PMC: 3111239. DOI: 10.1212/WNL.0b013e31821f4488. View

17.

Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, Head E . Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem. 2008; 284(7):4230-7. PMC: 2640961. DOI: 10.1074/jbc.M808591200. View

18.

Morris J . Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr. 1997; 9 Suppl 1:173-6; discussion 177-8. DOI: 10.1017/s1041610297004870. View

19.

Tomic J, Pensalfini A, Head E, Glabe C . Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis. 2009; 35(3):352-8. PMC: 2725199. DOI: 10.1016/j.nbd.2009.05.024. View

20.

Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A . Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008; 372(9634):216-23. DOI: 10.1016/S0140-6736(08)61075-2. View